Going the distance: reviewing antipsychotic depot or long-acting injectable treatments in Australasia.

Related Articles

Going the distance: reviewing antipsychotic depot or long-acting injectable treatments in Australasia.

Australas Psychiatry. 2018 Feb 01;:1039856218758559

Authors: Theodoros T, Taylor M, Huang HC, Wang N, Motamarri B

Abstract
OBJECTIVES: The aim of this study is to provide an opinion paper reviewing the role of depot or long-acting injectable (LAI) antipsychotic medications, with comments on individual newer LAIs such aripiprazole maintena and paliperidone palmitate. In particular, we share our recent experience of using paliperidone three-monthly LAI. We also reflect on the associated benefits and potential harms of LAIs, and when they may be used.
CONCLUSIONS: LAI antipsychotics are an important and arguably under-utilised therapeutic option, particularly where medication adherence is a priority, and where an informed patient opts for this formulation. Paliperidone is the first three-monthly LAI antipsychotic, and as such represents a significant advance in the range of treatment choices.

PMID: 29457473 [PubMed - as supplied by publisher]